Drug Profile
Research programme: antibody therapeutics - Regeneron/Sanofi
Alternative Names: ANG2 antibodies - Regeneron/Sanofi; Angiopoietin-2 antibodies - Regeneron/Sanofi; Anti-ANG2 antibodies - Regeneron/Sanofi; Anti-PDGF antibodies - Regeneron/Sanofi; Antibody collaboration - Regeneron/Sanofi; Therapeutic antibodies - Regeneron Pharmaceuticals/sanofi-aventisLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Class Antibodies; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiopoietin-2 inhibitors; CD223 antigen inhibitors; Immunomodulators; Platelet-derived growth factor receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; TNFRSF18 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Eye disorders; Unspecified
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for research development in Unspecified in USA (Parenteral)